{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:29:17Z","timestamp":1762475357804,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T00:00:00Z","timestamp":1648080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jdcr.2022.02.043","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T14:14:33Z","timestamp":1648822473000},"page":"97-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review"],"prefix":"10.1016","volume":"24","author":[{"given":"Duy C.","family":"Tran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Karim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Lo Sicco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nooshin","family":"Brinster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily C.","family":"Milam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian W.","family":"Tattersall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdcr.2022.02.043_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc3860","article-title":"PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting","volume":"15","author":"Thorpe","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"23","key":"10.1016\/j.jdcr.2022.02.043_bib2","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2018-05-850461","article-title":"The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL\/SLL","volume":"132","author":"Flinn","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jdcr.2022.02.043_bib3","first-page":"821","article-title":"PI3K inhibitors: understanding toxicity mechanisms and management","volume":"31","author":"Greenwell","year":"2017","journal-title":"Oncology (Williston Park)"},{"issue":"3","key":"10.1016\/j.jdcr.2022.02.043_bib4","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3783","article-title":"Psoriasiform eruption secondary to PI3K-delta inhibitor: expanding the spectrum of psoriasiform paradoxical reactions?","volume":"101","author":"Pesqu\u00e9","year":"2021","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.jdcr.2022.02.043_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jdcr.2018.03.005","article-title":"Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition","volume":"5","author":"Dewan","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"1","key":"10.1016\/j.jdcr.2022.02.043_bib6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13256-020-2344-9","article-title":"Management of psoriasis-like rash associated with idelalisib monotherapy in a patient with refractory follicular lymphoma: a case report","volume":"14","author":"Machan","year":"2020","journal-title":"J Med Case Rep"},{"issue":"8","key":"10.1016\/j.jdcr.2022.02.043_bib7","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/ced.13608","article-title":"Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition","volume":"43","author":"Dewan","year":"2018","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2022.02.043_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jinf.2008.04.005","article-title":"Trimethoprim-sulfamethoxazole induced erythrodermic psoriasis","volume":"57","author":"Esposito","year":"2008","journal-title":"J Infect"},{"issue":"2","key":"10.1016\/j.jdcr.2022.02.043_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jdcr.2022.02.043_bib10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00003727-198208000-00009","article-title":"Adverse drug reactions in the community health setting: approaches to recognizing, counseling, and reporting","volume":"5","author":"Jones","year":"1982","journal-title":"Fam Community Health"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512622001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:24:11Z","timestamp":1762475051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512622001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":10,"alternative-id":["S2352512622001692"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.02.043","relation":{},"ISSN":["2352-5126"],"issn-type":[{"type":"print","value":"2352-5126"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delayed-onset psoriasiform eruption secondary to a phosphoinositide 3-kinase inhibitor: A case report and literature review","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2022.02.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American Academy of Dermatology, Inc","name":"copyright","label":"Copyright"}]}}